The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Should see some great new investor exposure I'd Say!
Maybe they burn some old hemp for heating
Great listen
With proven track records within the organizations they work in.
We have already seen some excellent sector analysis which has been acted on.
We are now building our future on 3rd party money which is a masterclass move.
Medical cannabis drugs are not going away.
Those that currently use know they work.
Existing data sets and trials will put that In black and white.
Nhs is screaming out to treat chronic pain successfully at less cost.
I'm very very Bullish........
No point in selling 10k now 3k .
I hope your right , I won't hold me breath tho
If there was a big back ground buy, because boy is this cheap and whilst weak hands are happy to let some go and mms happy to pay 0.3 on the bid my guess is a buy to show
Deffo a strong hold if you know what your holding, weak hands and the unresearch will moan and groan about the current sp which is expected on low liquidity stocks but the end game will have the sellers weeping! But never mind they can buy their next stock high and sell low lol
This has always been a long term
Investment and we are nearing the end of our wait. Once trials have finished and been approved the sky will be the limit. Patience will be rewarded or sell if not so inclined.
Awarded for what exactly , definitely not for bringing profits to shareholders.
Begging bowl looms
Yup you and me suckered in ,£1 and 80p ,stupid stupid boy i never learn ,life style comp all day long
I bought this share in 2019 when medical cannabis was the buzz word .
0.80 I paid .
One peep said the ceo is Ponzi scheme artist
Wish I listened
We are certainly building out a company with a wealth of experience and proffession on board in order to become medical leader right here in the uk and beyond to serve this very much emerging sector in order to feed the NHS with hard evidence first then medicines as a result
'His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities.'
Looks to be gearing up for next stage objectives.
Biography
Vitalii holds a Master of Business Administration from the Kyiv University of Technology and Design, where he majored in Computer Science and minored in Behavioural Psychology. Vitalii has nine years of experience in the technology sector, beginning his career as a Data Engineer and Solution Architect for several Israeli companies. He has also been a foundational engineer in various start-ups, bringing his unique perspective and technical skills to the forefront of innovation. Vitalii currently works at an investment fund, where he creates quantitative models and tools to support investment decisions.
To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
Today 07:00
RNS Number : 0542C
Ananda Developments PLC
06 February 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Appoints Data and Analytics Expert
Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Vitalii Ratushnyi as an adviser to the Company with a focus on data and analytics.
Vitalii is a data, analytics, and quantitative modelling expert. His appointment gives Ananda the analytical capability to better target its research activities by identifying potential current and new disease areas where cannabinoids may be efficacious. His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities. The Company's objective is to provide the evidence required to get cannabis-based medicines available on the NHS.
Ananda CEO Melissa Sturgess commented "We believe our ability to get to grips with large biological and genetic data sets will help us find opportunities for our cannabinoid medicines, guide the design of clinical trials and will be a cornerstone of our success. This work is critical for the rapid development of our clinical trials pipeline and intellectual property estate."
Biog...
Worth half an hour of anybody’s time
Adviser Biographies
Professor Cherry Wainwright
Cherry graduated from the University of Aberdeen with a BSc (Hons) in Pharmacology and subsequently the University of Strathclyde with a PhD in Cardiovascular Pharmacology. Her research career spans more than 42 years, with over 20 years spent at Strathclyde University before moving to Robert Gordon University in Aberdeen where she spent 8 years as the Director of the multi-disciplinary Institute for Health & Wellbeing Research and was the lead in Cardiometabolic Health Research and Co-Director of the Centre for Natural Products in Health.
Throughout her career, Cherry has worked continuously in collaboration with industry conducting research on the identification of novel therapeutic targets of cardiovascular diseases. For the last 20 years her focus has been on the influence of endocannabinoids and phytocannabinoids on various cardiovascular disorders (ischaemia/reperfusion, cardiac fibrosis), vascular (atherosclerosis, restenosis) injury and cardiac energy regulation.
Cherry has published around 100 full original articles and invited reviews and holds 3 patents. She is a Fellow of the British Pharmacological Society, for which she is currently President Elect.
Dr. Katie Sloper, PhD
Katie graduated from the University of New England with a BSc in Biochemistry, Microbiology and Nutrition, receiving several university Prizes for Excellence. Katie was then the recipient of the University Medal at the Australian National University (ANU) for her Honours thesis on DNA damage repair pathways. Katie subsequently completed her PhD at ANU with a focus on cancer research, before completing postdoctoral fellowships in both Australia and the USA.
In addition to her medical research Katie has over 15 years working in healthcare across both public and private sectors, including as a Senior Policy Advisor to the Queensland Minister for Health and a Member of the Pharmacy Board of Australia. Katie's medical research has recently focussed on understanding the therapeutic profile of cannabis-based medicines and investigating innovative approaches to cancer treatment.